https://authors.elsevier.com/a/1jAE%7E5E-UogWnF: Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial